Alglucosidase alfa is an enzyme replacement therapy, sold under the brand names Myozyme and Lumizyme, developed as an orphan drug for Pompe disease, a rare lysosomal storage disorder. The therapy acts as a chemical analog of the enzyme patients with Pompe disease lack, and it was the first drug available to treat the condition, receiving United States Food and Drug Administration approval in April 2006.
Facts
Origin YearSourced to the subject's own account Sources
1. Wikipedia
Wikipedia contributors, Wikimedia Foundation
2. Alglucosidase Alfa (Wikipedia)
WikipediaLead section
It was approved for medical use in the United States in April 2006, as Myozyme and in May 2010, as Lumizyme.
https://en.wikipedia.org/wiki/Alglucosidase_alfa, lead section
Alglucosidase alfa, sold under the brand name Myozyme among others, is an enzyme replacement therapy (ERT) orphan drug for treatment of Pompe disease (Glycogen storage disease type II), a rare lysosomal storage disorder (LSD). Chemically, the drug is an analog of the enzyme that is deficient in patients affected by Pompe disease, alpha-glucosidase.
View the Source Frequently Asked Questions
Why does alglucosidase alfa have two brand names, Myozyme and Lumizyme?
It was approved in the United States as Myozyme in April 2006 and as Lumizyme in May 2010.
Alglucosidase alfa is an enzyme replacement therapy developed as an orphan drug for Pompe disease. It was approved for medical use in the United States in April 2006 under the brand name Myozyme, and in May 2010 under the brand name Lumizyme.
Reader Challenges (0)
No disputes yet. Spotted an error or a better source? Open the first one.
Sign in to dispute this or suggest a correction.
View At A Past Year
Choose a year to see this entry's facts and connections as the atlas records them at that moment: what it held then, what it held instead, and what it had not yet adopted. Choose Present for the current record.